| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6821992 | Schizophrenia Research | 2018 | 6 Pages |
Abstract
AOM 400 was well tolerated in patients continuing AOM treatment during the extension phase of the QUALIFY study. Robust and clinically meaningful improvements in health-related quality of life and functioning were maintained, further supporting the long-term clinical benefits of AOM 400 for the treatment of patients with schizophrenia.
Keywords
Aripiprazole once-monthlyEPSMMRMQLSC-SSRSFASAPTSQOLpaliperidone palmitateCGI-SQuality of lifeTEAESchizophreniaelectrocardiogramECGfull analysis setLong-Acting InjectableMaintenance treatmentLSMLAIadverse eventExtrapyramidal symptomstreatment-emergent adverse eventColumbia Suicide Severity Rating ScaleLeast squares meanQuality of Life Scale
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Dieter Naber, Ross A. Baker, Anna Eramo, Carlos Forray, Karina Hansen, Christophe Sapin, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Jean-Yves Loze, Steven G. Potkin,